Cipla Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Efficient capital deployment (ROCE 15.5%)
- Attractively valued vs sector (P/E 31.3x vs industry 54.7x)
- Virtually debt-free
Concerns
Today's Price Action
Cipla Limited (CIPLA) is trading at ₹1,385, unchanged from the previous close. The session sees a total volume of 13,26,027 shares, which exactly matches the 20‑day average volume, indicating that interest and liquidity remain consistent with recent trading patterns.
Valuation Snapshot
The stock’s trailing P/E stands at 32.1, considerably higher than the sector‑wide average, which is currently reported as zero (no sector peers with positive earnings). A price‑to‑book ratio of 0.0 combined with a return on equity of 11.6% points to a modest efficiency in generating earnings from shareholders’ capital.
Key Levels to Watch
The 52‑week price range spans ₹1,166 (low) to ₹1,673 (high). At ₹1,385 the share price sits roughly 31 % above the 52‑week low and about 17 % below the 52‑week high, suggesting it remains well within the established trading band. Open‑interest data, where available, shows notable concentrations around the ₹1,300 and ₹1,450 levels, which have historically acted as support and resistance zones.
Chart Pattern
In the daily timeframe, the last ten trading sessions produced a Dragonfly Doji three days ago, followed by a Hanging Man four days ago and an Evening Star five days ago. These candlesticks collectively illustrate short‑term indecision (Dragonfly Doji) transitioning into bearish momentum (Hanging Man and Evening Star), reflecting a shift in intra‑day price dynamics.
Data Summary
Key metrics for Cipla include a market capitalisation reported as ₹0 Cr, a trailing P/E of 32.1, and an ROE of 11.6 %. The share’s current price of ₹1,385 sits midway in its 52‑week range, with trading volume aligning precisely with the 20‑day average, underscoring stable market participation.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
| LUPIN Lupin Limited | ₹2,110 | ₹96K Cr | 16.2 | 4.3 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
CIPLA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 33.46% | 33.46% | 30.91% | 30.93% | 29.19% | 29.20% |
| FII | 25.73% | 25.82% | 27.82% | 28.80% | 26.65% | 26.28% |
| DII | 24.05% | 24.15% | 24.66% | 23.95% | 27.49% | 27.89% |
| Public | 16.53% | 16.36% | 16.40% | 16.11% | 16.43% | 16.36% |
| Govt | 0.21% | 0.21% | 0.21% | 0.21% | 0.23% | 0.26% |
Corporate Events
To consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended 30th June, 2026.In terms of the Company's Code of Conduct for prevention of Insider Trading, the 'Trading window' for dealing in the s
Dividend - Rs 13 Per Share
To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
Dividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share
Dividend - Rs 13 Per Share
Dividend - Rs 8.50 Per Share
Latest News
All newsCipla announces change in management team
Cipla Limited has announced a change in its management team, as per a regulatory filing with the NSE. Leadership transitions can impact strategic direction and execution in pharma firms. Such changes often trigger investor reassessment of governance and future outlook. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #ManagementChange
Cipla's USFDA inspects InvaGen facility in New York
*Cipla's USFDA inspects InvaGen facility in New York* — Cipla has announced a routine update regarding a USFDA inspection at its InvaGen manufacturing facility in Hauppauge, Long Island. The inspection is part of regular regulatory compliance checks. No **critical observations** or **adverse findings** have been reported so far. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Regulatory
Cipla to host analyst and investor meet
*Cipla to host analyst and investor meet.* The event is scheduled as part of its ongoing investor outreach. Details on strategic updates or financial performance may emerge. No immediate business or financial changes announced. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Cipla
US sanctions on Iran may impact Indian pharma, rice exports
*US sanctions on Iran may impact Indian pharma, rice exports.* Indian pharmaceutical and rice exporters face disruption due to tightening US sanctions on Iran. Key players like **SUNPHARMA**, **DRREDDY**, and **CIPLA** may see reduced shipments as trade channels dry up. Iranian market contributes **~$200M** to Indian pharma exports annually. 📊 *STOCKS:* SUNPHARMA, DRREDDY, CIPLA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Cipla updates on ESG ratings in corporate filing
*Cipla updates on ESG ratings in corporate filing.* The company filed general updates with the NSE, highlighting its latest ESG ratings. This disclosure is part of routine corporate compliance. No financial impact is expected from this update. 📊 *STOCKS:* $CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Cipla to host analyst and investor meet
*Cipla to host analyst and investor meet* to discuss business updates and strategy. The event is scheduled as per a recent NSE filing. No major financial announcements or guidance revision were disclosed. Investors await key insights on growth and margins. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Cipla
USFDA taps Zydus, Cipla to ease drug shortage
*USFDA taps Zydus, Cipla to ease drug shortage.* The USFDA has identified Zydus Lifesciences and Cipla as key suppliers to address the **ifosfamide** shortage in the US market. This presents a near-term export opportunity for both companies amid rising global demand. Regulatory approvals from USFDA could boost volumes and margins. 📊 *STOCKS:* ZYDUSLIFE, CIPLA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Cipla updates ESG rating in corporate filing
*Cipla updates ESG rating in corporate filing.* The company disclosed its latest ESG performance metrics in a regulatory filing. No financial figures or material events were announced. The update reflects ongoing sustainability disclosures. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Cipla grants stock options and SARs to employees
*Cipla grants stock options and SARs to employees*. Cipla Limited has announced the grant of stock options and employee stock appreciation rights (SARs) to its employees. The move is part of the company’s employee incentive program to retain and motivate talent. Specific numbers of options granted and eligible employees were not disclosed. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #StockOptions
Cipla updates on Verna manufacturing facility in Goa
*Cipla updates on Verna manufacturing facility in Goa.* The company provided general corporate updates regarding its facility in Verna, Goa. No financial or operational specifics were disclosed. Such routine updates typically have limited market impact. 📊 *STOCKS:* CIPLA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7.1K Cr 6.8% | ₹7.6K Cr 9.1% | ₹7.0K Cr 3.4% | ₹6.7K Cr 4.8% | ₹7.1K Cr 0.3% | ₹7.1K Cr 5.3% | ₹6.7K Cr 8.6% | ₹6.2K Cr |
| Op. Profit | ₹1.3K Cr 33.8% | ₹1.9K Cr 6.6% | ₹1.8K Cr 15.6% | ₹1.5K Cr 22.7% | ₹2.0K Cr 5.5% | ₹1.9K Cr 9.9% | ₹1.7K Cr 30.4% | ₹1.3K Cr |
| OPM | 18.0% 28.0% | 25.0% 3.8% | 26.0% 13.0% | 23.0% 17.9% | 28.0% 3.7% | 27.0% 3.8% | 26.0% 23.8% | 21.0% |
| Net Profit | ₹674 Cr 50.2% | ₹1.4K Cr 4.7% | ₹1.3K Cr 6.4% | ₹1.2K Cr 22.9% | ₹1.6K Cr 20.7% | ₹1.3K Cr 11.1% | ₹1.2K Cr 26.1% | ₹932 Cr |
| EPS (₹) | 8.37 50.0% | 16.73 4.2% | 16.06 6.1% | 15.13 22.2% | 19.45 20.6% | 16.13 10.6% | 14.58 25.4% | 11.63 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28.2K Cr 2.2% | ₹27.5K Cr 6.9% | ₹25.8K Cr 13.3% | ₹22.8K Cr 4.5% | ₹21.8K Cr 13.6% | ₹19.2K Cr 11.8% | ₹17.1K Cr 4.7% | ₹16.4K Cr 8.0% | ₹15.2K Cr 5.3% | ₹14.4K Cr |
| Expenses | ₹22.3K Cr 9.1% | ₹20.4K Cr 4.8% | ₹19.5K Cr 9.9% | ₹17.7K Cr 3.0% | ₹17.2K Cr 15.5% | ₹14.9K Cr 7.0% | ₹13.9K Cr 5.0% | ₹13.3K Cr 7.6% | ₹12.3K Cr 3.6% | ₹11.9K Cr |
| Op. Profit | ₹5.9K Cr 17.5% | ₹7.1K Cr 13.3% | ₹6.3K Cr 25.1% | ₹5.0K Cr 10.4% | ₹4.6K Cr 7.1% | ₹4.3K Cr 32.6% | ₹3.2K Cr 3.5% | ₹3.1K Cr 9.6% | ₹2.8K Cr 13.2% | ₹2.5K Cr |
| OPM | 21.0% 19.2% | 26.0% 8.3% | 24.0% 9.1% | 22.0% 4.8% | 21.0% 4.5% | 22.0% 15.8% | 19.0% 0.0% | 19.0% 0.0% | 19.0% 11.8% | 17.0% |
| Other Income | ₹606 Cr 29.7% | ₹862 Cr 56.2% | ₹552 Cr 88.4% | ₹293 Cr 196.0% | ₹99 Cr 62.8% | ₹266 Cr 22.7% | ₹344 Cr 27.9% | ₹477 Cr 70.4% | ₹280 Cr 34.6% | ₹208 Cr |
| Interest | ₹54 Cr 12.9% | ₹62 Cr 31.1% | ₹90 Cr 18.2% | ₹110 Cr 3.8% | ₹106 Cr 34.2% | ₹161 Cr 18.3% | ₹197 Cr 17.3% | ₹168 Cr 47.4% | ₹114 Cr 28.3% | ₹159 Cr |
| Depreciation | ₹1.2K Cr 9.4% | ₹1.1K Cr 5.3% | ₹1.1K Cr 10.3% | ₹1.2K Cr 11.4% | ₹1.1K Cr 1.5% | ₹1.1K Cr 9.1% | ₹1.2K Cr 11.4% | ₹1.3K Cr 0.2% | ₹1.3K Cr 0.0% | ₹1.3K Cr |
| PBT | ₹5.2K Cr 23.4% | ₹6.8K Cr 19.6% | ₹5.7K Cr 41.2% | ₹4.0K Cr 15.6% | ₹3.5K Cr 6.2% | ₹3.3K Cr 51.1% | ₹2.2K Cr 4.8% | ₹2.1K Cr 24.6% | ₹1.7K Cr 36.6% | ₹1.2K Cr |
| Tax % | 26.0% 18.2% | 22.0% 18.5% | 27.0% 10.0% | 30.0% 11.1% | 27.0% 0.0% | 27.0% 6.9% | 29.0% 7.4% | 27.0% 80.0% | 15.0% 0.0% | 15.0% |
| Net Profit | ₹3.9K Cr 26.7% | ₹5.3K Cr 26.8% | ₹4.2K Cr 46.6% | ₹2.8K Cr 11.2% | ₹2.5K Cr 6.6% | ₹2.4K Cr 59.3% | ₹1.5K Cr 0.5% | ₹1.5K Cr 5.3% | ₹1.4K Cr 36.9% | ₹1.0K Cr |
| EPS (₹) | 48.02 26.4% | 65.28 27.9% | 51.05 47.1% | 34.71 11.3% | 31.19 4.6% | 29.82 55.5% | 19.18 1.2% | 18.96 8.2% | 17.52 40.0% | 12.51 |
| Div Payout | 27.0% 8.0% | 25.0% 0.0% | 25.0% 4.2% | 24.0% 50.0% | 16.0% 5.9% | 17.0% 19.0% | 21.0% 31.3% | 16.0% 5.9% | 17.0% 6.3% | 16.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹162 Cr 0.0% | ₹162 Cr 0.6% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr 0.0% | ₹161 Cr |
| Reserves | ₹32.8K Cr 5.6% | ₹31.0K Cr 16.9% | ₹26.5K Cr 14.2% | ₹23.2K Cr 12.4% | ₹20.7K Cr 13.8% | ₹18.2K Cr 16.4% | ₹15.6K Cr 5.1% | ₹14.9K Cr 5.6% | ₹14.1K Cr 13.6% | ₹12.4K Cr |
| Borrowings | ₹467 Cr 6.6% | ₹438 Cr 21.6% | ₹559 Cr 30.4% | ₹803 Cr 24.0% | ₹1.1K Cr 47.6% | ₹2.0K Cr 28.5% | ₹2.8K Cr 34.8% | ₹4.3K Cr 5.3% | ₹4.1K Cr 0.4% | ₹4.1K Cr |
| Other Liabilities | ₹6.8K Cr 18.9% | ₹5.7K Cr 8.3% | ₹5.3K Cr 3.5% | ₹5.1K Cr 2.6% | ₹5.0K Cr 9.9% | ₹4.5K Cr 6.8% | ₹4.8K Cr 9.2% | ₹4.4K Cr 2.0% | ₹4.3K Cr 3.2% | ₹4.2K Cr |
| Total Liabilities | ₹40.2K Cr 7.6% | ₹37.3K Cr 14.8% | ₹32.5K Cr 11.0% | ₹29.3K Cr 9.1% | ₹26.9K Cr 8.1% | ₹24.9K Cr 6.1% | ₹23.4K Cr 1.4% | ₹23.8K Cr 4.8% | ₹22.7K Cr 8.6% | ₹20.9K Cr |
Assets | ||||||||||
| Fixed Assets | ₹10.9K Cr 9.3% | ₹10.0K Cr 4.2% | ₹9.6K Cr 4.9% | ₹9.2K Cr 5.4% | ₹9.7K Cr 1.8% | ₹9.5K Cr 1.7% | ₹9.7K Cr 0.8% | ₹9.6K Cr 3.4% | ₹9.9K Cr 4.8% | ₹9.5K Cr |
| CWIP | ₹1.4K Cr 8.2% | ₹1.6K Cr 35.8% | ₹1.2K Cr 5.5% | ₹1.1K Cr 42.7% | ₹766 Cr 20.9% | ₹969 Cr 17.5% | ₹825 Cr 22.0% | ₹676 Cr 31.1% | ₹981 Cr 41.7% | ₹1.7K Cr |
| Investments | ₹8.2K Cr 3.6% | ₹7.9K Cr 45.6% | ₹5.4K Cr 48.8% | ₹3.7K Cr 43.6% | ₹2.6K Cr 5.9% | ₹2.7K Cr 84.2% | ₹1.5K Cr 42.4% | ₹2.6K Cr 102.9% | ₹1.3K Cr 29.4% | ₹973 Cr |
| Other Assets | ₹19.6K Cr 9.8% | ₹17.8K Cr 9.2% | ₹16.3K Cr 6.1% | ₹15.4K Cr 11.0% | ₹13.9K Cr 18.8% | ₹11.7K Cr 1.9% | ₹11.4K Cr 4.8% | ₹10.9K Cr 4.2% | ₹10.5K Cr 20.2% | ₹8.7K Cr |
| Total Assets | ₹40.2K Cr 7.6% | ₹37.3K Cr 14.8% | ₹32.5K Cr 11.0% | ₹29.3K Cr 9.1% | ₹26.9K Cr 8.1% | ₹24.9K Cr 6.1% | ₹23.4K Cr 1.4% | ₹23.8K Cr 4.8% | ₹22.7K Cr 8.6% | ₹20.9K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹5.0K Cr 21.1% | ₹4.1K Cr 27.7% | ₹3.2K Cr 2.6% | ₹3.3K Cr 11.4% | ₹3.8K Cr 22.4% | ₹3.1K Cr 81.4% | ₹1.7K Cr 15.6% | ₹1.5K Cr 38.6% | ₹2.4K Cr 36.8% | ₹1.7K Cr |
| Investing CF | ₹-3.7K Cr 23.5% | ₹-3.0K Cr 25.5% | ₹-2.4K Cr 27.9% | ₹-1.9K Cr 21.7% | ₹-2.4K Cr 2182.5% | ₹114 Cr 106.8% | ₹-1.7K Cr 102.4% | ₹-834 Cr 36.0% | ₹-1.3K Cr 71.2% | ₹-4.5K Cr |
| Financing CF | ₹-1.3K Cr 7.8% | ₹-1.2K Cr 25.3% | ₹-958 Cr 40.1% | ₹-1.6K Cr 29.0% | ₹-1.2K Cr 58.0% | ₹-2.9K Cr 745.0% | ₹-349 Cr 9.4% | ₹-385 Cr 71.0% | ₹-1.3K Cr 142.7% | ₹3.1K Cr |
| Net Cash Flow | ₹30 Cr 161.2% | ₹-49 Cr 49.5% | ₹-97 Cr 26.5% | ₹-132 Cr 193.6% | ₹141 Cr 39.7% | ₹234 Cr 167.8% | ₹-345 Cr 242.0% | ₹243 Cr 198.0% | ₹-248 Cr 179.5% | ₹312 Cr |
| Free Cash Flow | ₹3.5K Cr 23.8% | ₹2.8K Cr 34.1% | ₹2.1K Cr 20.5% | ₹2.6K Cr 10.8% | ₹3.0K Cr 42.3% | ₹2.1K Cr 75.5% | ₹1.2K Cr 64.2% | ₹723 Cr 43.7% | ₹1.3K Cr 86.6% | ₹688 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73d 7.4% | 68d 4.6% | 65d 14.0% | 57d 13.6% | 66d 20.5% | 83d 10.8% | 93d 24.0% | 75d 15.4% | 65d 4.8% | 62d |
| Inventory Days | 231d 6.5% | 217d 4.8% | 228d 0.9% | 230d 0.9% | 232d 13.1% | 267d 6.8% | 250d 7.7% | 271d 13.4% | 239d 12.5% | 273d |
| Days Payable | 116d 13.7% | 102d 8.9% | 112d 3.7% | 108d 4.9% | 103d 25.9% | 139d 13.0% | 123d 13.4% | 142d 31.5% | 108d 1.9% | 106d |
| Cash Conv. Cycle | 188d 3.3% | 182d 0.6% | 181d 0.6% | 180d 7.7% | 195d 7.6% | 211d 4.1% | 220d 7.8% | 204d 4.1% | 196d 14.8% | 230d |
| Working Capital Days | 128d 6.7% | 120d 6.2% | 113d 18.9% | 95d 1.1% | 94d 16.8% | 113d 14.4% | 132d 11.9% | 118d 19.2% | 99d 1090.0% | -10d |
| ROCE | 23.0% 0.0% | 23.0% 27.8% | 18.0% 5.9% | 17.0% 0.0% | 17.0% 41.7% | 12.0% 9.1% | 11.0% 22.2% | 9.0% 28.6% | 7.0% 46.2% | 13.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Cipla Limited
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]
HealthcarePharmaceuticals & Biotechnology